A prospective, observational, study of Pharmaco-invasive Strategy with Reteplase in Indian patients with STEMI - RePAMI

STEMI INDIA0 个研究点目标入组 200 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Adults 18 to 75 years of age complaining of chest pain, discomfort and/or indications of STEMI requiring either primary PCI or pharmaco-invasive treatment with Reteplace will be included in the study.
•2.Patients presenting with the onset of symptoms within 12 hours.
•3.ST elevation New ST elevation at the J point in two contiguous leads with the cut-points: > 0.1 mV in all leads other than leads V2â??V3 where the following cut points apply: > 0.2 mV in men > 40 years; > 0.25 mV in men < 40 years, or > 0.15 mV in women.
•4.Subjects / LAR or impartial witness (if applicable) must be able to understand and provide their consent in the informed consent form

•1.Previous enrollment in this study or treatment with the investigational drug or participating in any other study in the past 30 days
•2.Patients who are unwilling to participate in the study or sign the informed consent

发起方

STEMI INDIA